CA
NZ
UK
AU
IND
US
Hims & Hers Health has become a focal point for options traders seeking dual profit opportunities as the stock’s technical strength solidifies. The telehealth company’s shares have established a clear uptrend, with price action forming successive higher lows and higher highs while maintaining support …
EnGene Therapeutics has appointed a new chairman to guide its board through a key regulatory phase, as the company advances toward a potential 2027 regulatory decision for its lead bladder cancer gene therapy. Michael Heffernan, a biopharmaceutical executive with extensive industry experience, assumed the …
The company’s shares responded instantly, rising more than ten percent to close at $98.81. This price action follows a year‑to‑date decline of roughly twenty percent, yet the stock has rallied over eleven percent in the past month. The market now values the company at …
Arbutus Biopharma (NASDAQ: ABUS) has formally ended a 2025 patent collaboration with Genevant Sciences that was linked to Moderna’s respiratory syncytial virus (RSV) vaccine program. This step follows a settlement with Moderna that delivered approximately $178 million to Arbutus, bringing closure to a series …
Cardiff Oncology has completed a $10.05 million stock offering, reinforcing its financial position as it navigates a challenging period for biotech stocks. The company sold 8,571,429 shares at $1.3125 per share, a price set above recent trading levels, alongside warrants that allow investors to …
CDT Equity Inc. The company’s board, acting under prior stockholder authorization, cited compliance with Nasdaq’s minimum bid-price rule as the primary driver for the consolidation. Fractional shares will not be issued; instead, shareholders will receive cash equal to the fractional value multiplied by the …
Eleven U.S. states are emerging as leaders in workforce development, positioning themselves for stronger economic growth and job market resilience by 2026. These regions excel in education levels, migration trends, and targeted training programs, creating a competitive edge as artificial intelligence reshapes entry-level employment.
Abbott Laboratories delivered stronger-than-expected second-quarter earnings and lifted its full-year profit outlook, signaling momentum in its medical device and diagnostics businesses despite softness in nutrition.
The blockage stems from objections to provisions that critics argue could expand US military involvement in Iran, alongside concerns over Israel’s integration into regional defense strategies. The impasse leaves the Pentagon’s funding in limbo, with no clear path forward for the legislation, which supports …
Jay Clayton’s refusal to declare that President Biden won the 2020 election during his appearance before the Senate Intelligence Committee has stalled the confirmation process for the top U.S. intelligence post. The standoff injected heightened partisan tension into a normally low‑profile appointment, prompting market …
Please wait processing your request...